introduction multiple sclerosis immune-mediated disorder central nervous system cns characterized clinical relapse associated acute focal brain inflammation progressive worsening disability accompanying neurodegeneration disease outcome highly variable person pwms injury contributing disease occurs across disease course whether presence absence relapse current disease-modifying therapy dmts effectively suppress acute disease activity development novel treatment effectively reduce disability progression remains unmet need strong genetic component risk confirmed genome-wide significant variant along variant extended major histocompatibility complex mhc region account approximately 38.2 overall heritability locus primarily affect immune system supporting autoimmune hypothesis pathogenesis use available immune-modulating dmts recently large study highlighted importance cns resilience severity furthermore observe overlap severity susceptibility locus however little known genetics progression may also differ genetics susceptibility paucity progression genetics knowledge could possibly due lack meaningful longitudinal data scale previous study used cross-sectional imaging trait non-linear disability severity score investigate severity additionally measuring disease progression using clinical outcome challenging expanded disability severity score eds commonly used measure worsening partially capture underlying insidious injury similarly clinical relapse early stage predict long-term outcome natural history study therefore leveraged longitudinal imaging data unique dataset randomized controlled trial rcts conducted biogen roche/genentech precompetitive partnership examine genetics progression investigated genetic correlate two longitudinal quantitative brain mri outcome change brain volume change lesion volume t2lv change measure overall impact injury including demyelination neurodegeneration rate brain atrophy time quantitative measure correlate worsening clinical disability t2lv increase accumulating injury early measure t2lv may predictive long-term disability deeper understanding genetic factor impact rate progression could reveal novel candidate target biomarkers relevant progressive biology material method standard protocol approval registration patient consent performed gwas change t2lv change across six rcts advance trial registry number nct00906399 ascend trial registry number nct01416181 decide trial registry number nct01064401 opera trial registry number nct01247324 nct01412333 oratorio trial registry number nct01194570 etables participant provided written informed consent covered scope research ethical approval provided per original rcts work adheres declaration helsinki image acquisition trait estimation t1-weighted proton density-weighted t2-weighted brain mri collected accordance standardized imaging protocol trial trial used centralized mri reading center neurorx montreal canada change measured week last time point available participant using automated siena structural image evaluation using normalization atrophy method used week instead baseline account potential rapid volume change related resolution acute inflammation following treatment initiation also known pseudoatrophy placebo arm patient advance change calculated baseline week participant switched active treatment calculate t2lv lesion segmented using fully-automated method followed visual verification adjustment needed t2lv change estimated change total t2lv baseline last time point available participant placebo arm advance used week instead last time point consistent change estimation within rct change t2lv annualized account varying length follow-up time trial accomplished dividing individual change number year first last time point used estimation annualized trait transformed using rank-based inverse normal transformation mitigate departure normality efigures genetic data generation quality control advance ascend decide biogen trial dna extracted blood genotyped affymetrix biobank axiom array thermo fisher scientific santa clara two batch ascend decide advance plink v1.9 imputation michigan imputation server run batch separately hg19 excluded single nucleotide polymorphism snp missingness minor allele frequency maf 0.01 hardy–weinberg equilibrium hwe –50 case-only cohort applied stringent hwe threshold avoid inadvertent exclusion disease-associated variant excluded sample missingness sex discrepancy female 0.2 male 0.8 excess heterozygosity standard deviation mean relatedness independent snp plink option indep-pairwise 0.5 used estimate sex heterozygosity relatedness ancestry identity descent ibd analysis used identify related individual pair individual 0.4 considered related one member pair selected randomly exclusion estimated ancestry separately rct used principal component analysis pca smartpca eigensoft v7.2.1 identify outlier calculate excluded individual standard deviation top maximum outlier removal iteration default estimated tracy-widom statistic determine number include covariates defined 0.05 accounted variance calculated subtracting largest eigenvalue 0.05 sum eigenvalue 0.05 estimating relative contributing variance genotype imputed 1000g phase3v5 phasing shapeit v2.r790 imputation excluded snp 0.30 maf 0.01 pseudo-autosomal region chromosome snp sample step tabulated etable opera opera oratorio roche trial dna extracted blood whole-genome sequenced wgs mean read depth 30x truseq nano library prep illumina hiseq generate paired-end read illumina inc foster city burrows-wheeler aligner bwa used map read hg38 resulting alignment bam file analyzed using gatk base quality score recalibration bqsr indel realignment duplicate removal snp/indel discovery joint genotyping across sample according gatk best practice site pas gatk variant quality score recalibration vqsr filter removed genotype quality score set missing followed removal site missing rate improve coverage common variant genotype imputation performed using haplotype reference panel 55,929 individual constructed using 27,166 individual haplotype reference consortium sample genome project 26,215 sample sequenced genentech imputation performed using beagle version 5.2 site imputation score 0.3 hwe –10 maf removed ancestry estimated using admixture supervised mode reference 1000g phase3 sample european ancestry coefficient 0.7 excluded analysis heterozygosity outlier detection relatedness ibd pair individual 0.4 considered related statistic pca performed similarly biogen gwas statistical analysis used linear regression model test association snp change t2lv change additive model controlling randomized treatment arm age sex genetic ancestry advance decide ascend opera oratorio biogen analysis performed using imputed dosage plink v2.0 option glm maf 0.01 genentech analysis performed using wgs plink v1.9 option linear maf 0.01 summary statistic roche rcts mapped hg38 hg19 using liftover hail summary statistic rcts meta-analyzed using fixed-effects model plink v1.9 regional plot generated locuszoom v1.4 1000g phase3 eur increase power beyond single variant analysis used magma evaluate association gene level using meta-analyzed summary statistic used recent version magma 1.10 reference data provided author magma generated phase genome project used bonferroni correction determine significance threshold 0.05/17,837 gene 2.6 colocalization analysis better understand gene top hit change t2lv change may impact performed colocalization adapted coloc package human expression data gtex tissue http database immune cell eqtls http also examined evidence shared causal variant selected risk locus top hit analysis included snp within window region query study snp static default prior probability p12 cns cell-type specific expression visualize single-nucleus gene expression putative gene identified gwas meta-analysis cns cell type used cellxgene vip http based brain tissue patient comparison risk snp examined autosomal risk gwas locus including peak variant mhc potential association change t2lv selected available overlapping variant wgs genotype data report association statistic variant whose effect change t2lv change consistent across six rcts heterogeneity additionally generated polygenic risk score using non-mhc variant weight imsgc risk discovery gwas tested score association change t2lv change result gwas meta-analysis included participant change participant t2lv change rcts relapsing remitting rrms advance t2lv change data respectively decide opera opera secondary progressive spms ascend primary progressive ppms oratorio table participant mainly female 51–74 mean age higher rcts 45–47 36–38 rrms mean study duration 1.8 year total meta-analyzed 10,382,375 10,608,740 snp association change t2lv change respectively genomic inflation factor show evidence bias ancestry either gwas 1.008 t2lv 1.019 efigure table sample characteristic study population full size table significant association change intronic snp ptprd top snp rs77321193-c/a 5.3 showed evidence heterogeneity across trial heterogeneity heterogeneity 0.96 fig table minor allele maf 0.18 rs77321193 associated greater reduction time multiple snp region showed association change similar effect size evidence heterogeneity meta-analysis etable fig observe colocalization ptprd peak expression ptprd datasets evaluated however analysis cell-type specific gene expression brain fig revealed ptprd expressed neuron oligodendrocyte oligodendrocyte precursor cell gene-based test reveal significant association ptprd 0.066 gene top hit tspan8 8.08 etable figure genome-wide association plot meta-analysis change brain volume lesion volume t2lv gwas study manhattan plot negative log p-values y-axis chromosome position hg19 x-axis point corresponds single snp analyzed gwas change t2lv change horizontal purple line indicates genome-wide significance threshold peak snp labeled closest gene brain volume gwas genome-wide association study nedd4l neural precursor cell-expressed developmentally down-regulated 4-like ptprd protein tyrosine phosphatase receptor type snp single nucleotide polymorphism t2lv lesion volume full size image table peak snp meta-analysis change brain volume gwas study full size table figure regional association plot peak snp meta-analysis change brain volume lesion volume t2lv gwas study regional association plot negative log p-values primary y-axis genetic recombination rate secondary y-axis chromosome position hg19 x-axis point corresponds single snp analyzed gwas correlation peak snp proxy snp snp region reflected linkage disequilibrium estimate depicted blue least correlation 0.2 red correlation 0.8 plot created using locuszoom http depict association change intronic snp rs77321193 ptprd chromosome t2lv change regulatory snp rs11398377 near nedd4l chromosome proxy snp rs9955426 used plot rs11398377 present reference panel 1000g eur 1000g eur genome european brain volume gwas genome-wide association study nedd4l neural precursor cell-expressed developmentally down-regulated 4-like ptprd protein tyrosine phosphatase receptor type snp single nucleotide polymorphism t2lv lesion volume full size image figure forest plot peak snp meta-analysis change brain volume lesion volume t2lv gwas study forest plot depicting trial-wise black square meta-analyzed summary blue diamond association peak variant rs77321193 chromosome change effect allele heterogeneity 0.01 0.95 proxy snp peak variant rs9955426 chromosome t2lv change effect allele heterogeneity 0.10 effect size reported beta x-axis sample size reported along trial name strength association reported p-values direction association indicated color scale bottom plot brain volume gwas genome-wide association study nedd4l neural precursor cell-expressed developmentally down-regulated 4-like ptprd protein tyrosine phosphatase receptor type snp single nucleotide polymorphism t2lv lesion volume full size image figure dot plot cns cell-type specific expression ptprd nedd4l brain tissue cns central nervous system excitatory neuron inter-neuron l2-3 upper layer cortical projection layer cortical projection l5-6 deep layer cortical projection mix mixed multiple sclerosis oligodendrocyte opc oligodendrocyte progenitor cell pyr pyramidal cell pvalb parvalbumin sst somatostatin sv2c synaptic vesicle glycoprotein vip vasoactive intestinal peptide full size image strongest association t2lv change regulatory region near nedd4l top snp rs11398377-gc/g 9.5 consistent across trial heterogeneity heterogeneity 0.07 fig table deletion rs11398377 maf 0.16 associated greater t2lv accumulation time several snp region associated t2lv change similar effect size show significant heterogeneity meta-analysis etable fig interestingly found evidence colocalization t2lv change peak rs11398377 nedd4l expression whole blood colocalization pp4 0.78 suggestive common causal variant trait moreover analysis cell-specific gene expression brain showed nedd4l expressed mainly neuron including inter-neurons excitatory neuron fig gene-based test show significant association change t2lv top hit wdr34 2.0 however nedd4l among top hit 6.94 etable table peak snp meta-analysis change t2lv gwas study full size table comparison known risk gwas snp non-mhc autosomal snp met inclusion criterion comparison change t2lv change meta-analyses result respectively show evidence overlap change t2lv change gwas hit etables observe significant association susceptibility locus change t2lv change found overlap risk locus mhc region conversely neither change peak ptprd t2lv change peak nedd4l associated risk putative change t2lv change peak colocalized risk additionally risk significantly associated change 0.54 change t2lv 0.89 discussion knowledge first gwas meta-analysis longitudinal mri measure across multiple rcts investigate genetics progression achieved leveraging precompetitive industry partnership aimed utilizing well-characterized cohort interrogate genetics disease progression top change snp occurs intron ptprd protein tyrosine phosphatase receptor involved cellular signaling growth differentiation previous study cross-sectional multiple sclerosis severity score also reported sub-significant association variant ptprd region independent change peak cross sectional top snp top snp rs1953594 adjusted trend logp 4.3 top snp rs10977017 1.02 additionally variant mapped ptprd associated two sleep disorder enriched pwms restless leg syndrome top snp rs1836229 insomnia top snp rs10761240 observe evidence colocalization top change association ptprd expression possible study insufficiently powered detect colocalization locus impact mechanism time-dependent cell lineage-specific independent ptprd expression top t2lv association indel snp lie regulatory region upstream nedd4l nedd4l neural precursor cell expressed developmentally down-regulated 4-like play role axon guidance neurite growth synaptic transmission pain sensitivity nedd4l peak showed evidence colocalization expression nedd4l blood gtex minor allele top snp rs11398377 deletion associated greater t2lv accumulation increased gene expression indicating downregulation gene may therapeutic potential missense snp nedd4l cause abnormal fetal neurodevelopment brain malformation periventricular nodular heterotopia nedd4l encodes ubiquitin-protein ligase regulates several membrane channel transporter including epithelial enac voltage-gated nav sodium channel enacs navs implicated demyelination pathophysiology research ongoing investigate role sodium channel blocker preventing axonal damage link supported use channel blocker dalfampridine improvement walking pwms t2lv change trait may correlated etable reflect complementary measure progressive biology—bv reduction represents global measure brain tissue loss t2lv increase reflects immune-mediated injury cns white matter ptprd nedd4l strongly expressed cns particularly neuron ptprd also abundant oligodendrocyte oligodendrocyte precursor cell oligodendrocyte play important role myelinate neuron nedd4l paralog nedd4 promotes ubiquitination degradation rapgef2 one putative risk gene enhanced single cell expression cns cell imsgc recently published large study severity using age-related severity score arms reported association dysf–znf638 locus additionally smaller study individual examining median longitudinal arms l-armss longitudinal l-msss find significant association imsgc dysf–znf638 locus index variant rs10191329 associated change beta 0.004 0.91 change t2lv analysis beta 0.07 0.04 may due greater power imsgc analysis also possible variable analyzed capture different aspect disease course chose focus objective imaging measure rather clinical measure eds arms variable based due certain limitation measure instance eds score numerical nonlinear ranging largely based mobility making poor proxy progression similar imsgc severity study find overlap risk locus peak observe association suggests mechanism driving susceptibility may differ modulating outcome influencing disease progression prior study patient found strongest genetic risk factor hla- drb1 15:01 associated reduction brain parenchymal volume higher lesion load however finding replicated study acknowledge following limitation study two rcts ascend oratorio examined rrms participant possible biological mechanism underlying progression differ early-stage late-stage moreover clinical trial participant may representative general population owing strict inclusion exclusion criterion used participant selection rcts neither peak identified study reached genome-wide significance stricter threshold 2.5 account multiple testing though powered detect moderate association common snp ability detect genome-wide association would improved larger sample size additional well-characterized cohort needed independent replication longitudinal mri data available year however reflects small proportion average patient disease course longer follow-up would provide accurate outcome t2lv change several trial additional longitudinal data available open label extension study however including data would introduced complexity variable length follow-up differential handling placebo treatment arm accounting pseudoatrophy treatment initiation therefore limited analysis data placebo-controlled period endeavored account pseudoatrophy re-baselining week possible fully capture pseudoatrophy chose re-baseline using week measure reasonable duration mri follow-up gwas work highlight utility using clinical trial data genetic analysis rcts assigned treatment arm systematic imaging collection genetic analysis rcts uniquely positioned leverage objective quantitative measurement advance understanding disease course furthermore mri analysis method used quantify atrophy t2lv standardized within study extent possible across study used meta-analysis study utilized centralized mri reading center neurorx finally finding complement existing risk study identifying additional genetic factor related different aspect disease conclusion study identified two novel putative locus ptprd nedd4l may impact disease progression investigation additional cohort warranted validate finding